ETS variant 1 regulates matrix metalloproteinase-7 transcription in LNCaP prostate cancer cells

Oncology Reports

Volumn 29, Issue 1, 2013, Pages 306-314

  Shin, Sook ^a   Oh, Sangphil ^a   An, Seayoon ^a   Janknecht, Ralf ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Cell migration; ETS transcription factor; ETS variant 1; Gene transcription; Matrix metalloproteinase 7; Prostate cancer

Indexed keywords

ETS1 PROTEIN; MATRILYSIN; MESSENGER RNA; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; ETV1 PROTEIN, HUMAN; LUCIFERASE; MMP7 PROTEIN, HUMAN; SMALL INTERFERING RNA; TUMOR MARKER;

ARTICLE; BASE PAIRING; BINDING SITE; CANCER CELL; CANCER STAGING; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ETS1 GENE; GENE INTERACTION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC VARIABILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MMP 7 GENE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; TRANSCRIPTION REGULATION; APOPTOSIS; CELL MOTION; CHROMATIN IMMUNOPRECIPITATION; DRUG ANTAGONISM; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROGNOSIS; PROSTATE TUMOR; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION INITIATION; TUMOR CELL CULTURE; WESTERN BLOTTING;

APOPTOSIS; BASE SEQUENCE; BLOTTING, WESTERN; CELL MOVEMENT; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; DNA-BINDING PROTEINS; ELECTROPHORETIC MOBILITY SHIFT ASSAY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUCIFERASES; MALE; MATRIX METALLOPROTEINASE 7; MOLECULAR SEQUENCE DATA; NEOPLASM STAGING; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS; TRANSCRIPTIONAL ACTIVATION; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 84872861372     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.2079     Document Type: Article

References (87)

1. Brown TA and McKnight SL: Specificities of protein-protein and protein-DNA interaction of GABP alpha and two newly defined ets-related proteins. Genes Dev 6: 2502-2512, 1992.
2. Coutte L, Monte D, Imai K, Pouilly L, Dewitte F, Vidaud M, Adamski J, Baert JL and de Launoit Y: Characterization of the human and mouse ETV1/ER81 transcription factor genes: role of the two alternatively spliced isoforms in the human. Oncogene 18: 6278-6286, 1999.
3. Sharrocks AD: The ETS-domain transcription factor family. Nat Rev Mol Cell Biol 2: 827-837, 2001.
4. Hollenhorst PC, McIntosh LP and Graves BJ: Genomic and biochemical insights into the specificity of ETS transcription factors. Annu Rev Biochem 80: 437-471, 2011.
5. Oh S, Shin S and Janknecht R: ETV1, 4 and 5: An oncogenic subfamily of ETS transcription factors. Biochim Biophys Acta 1826: 1-12, 2012.
6. Jeon IS, Davis JN, Braun BS, Sublett JE, Roussel MF, Denny CT and Shapiro DN: A variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1. Oncogene 10: 1229-1234, 1995.
7. Monte D, Coutte L, Baert JL, Angeli I, Stehelin D and de Launoit Y: Molecular characterization of the ets-related human transcription factor ER81. Oncogene 11: 771-779, 1995.
8. Chotteau-Lelievre A, Desbiens X, Pelczar H, Defossez PA and de Launoit Y: Differential expression patterns of the PEA3 group transcription factors through murine embryonic development. Oncogene 15: 937-952, 1997.
9. Chotteau-Lelievre A, Dolle P, Peronne V, Coutte L, de Launoit Y and Desbiens X: Expression patterns of the Ets transcription factors from the PEA3 group during early stages of mouse development. Mech Dev 108: 191-195, 2001.
10. Arber S, Ladle DR, Lin JH, Frank E and Jessell TM: ETS gene Er81 controls the formation of functional connections between group Ia sensory afferents and motor neurons. Cell 101: 485-498, 2000.
11. Kucera J, Cooney W, Que A, Szeder V, Stancz-Szeder H and Walro J: Formation of supernumerary muscle spindles at the expense of Golgi tendon organs in ER81-deficient mice. Dev Dyn 223: 389-401, 2002.
12. Janknecht R: Analysis of the ERK-stimulated ETS transcription factor ER81. Mol Cell Biol 16: 1550-1556, 1996.
13. Bosc DG, Goueli BS and Janknecht R: HER2/Neu-mediated activation of the ETS transcription factor ER81 and its target gene MMP-1. Oncogene 20: 6215-6224, 2001.
14. Janknecht R: Cell type-specific inhibition of the ETS transcription factor ER81 by mitogen-activated protein kinase-activated protein kinase 2. J Biol Chem 276: 41856-41861, 2001.
15. Wu J and Janknecht R: Regulation of the ETS transcription factor ER81 by the 90-kDa ribosomal S6 kinase 1 and protein kinase A. J Biol Chem 277: 42669-42679, 2002.
16. Janknecht R: Regulation of the ER81 transcription factor and its coactivators by mitogen- and stress-activated protein kinase 1 (MSK1). Oncogene 22: 746-755, 2003.
17. Papoutsopoulou S and Janknecht R: Phosphorylation of ETS transcription factor ER81 in a complex with its coactivators CREB-binding protein and p300. Mol Cell Biol 20: 7300-7310, 2000.
18. Goel A and Janknecht R: Acetylation-mediated transcriptional activation of the ETS protein ER81 by p300, P/CAF, and HER2/Neu. Mol Cell Biol 23: 6243-6254, 2003.
19. Janknecht R: The versatile functions of the transcriptional coactivators p300 and CBP and their roles in disease. Histol Histopathol 17: 657-668, 2002.
20. Lee KK and Workman JL: Histone acetyltransferase complexes: one size doesn't fit all. Nat Rev Mol Cell Biol 8: 284-295, 2007.
21. Goel A and Janknecht R: Concerted activation of ETS protein ER81 by p160 coactivators, the acetyltransferase p300 and the receptor tyrosine kinase HER2/Neu. J Biol Chem 279: 14909-14916, 2004.
22. Font de Mora J and Brown M: AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol Cell Biol 20: 5041-5047, 2000.
23. Xu J, Wu RC and O'Malley BW: Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family. Nat Rev Cancer 9: 615-630, 2009.
24. Janknecht R: EWS-ETS oncoproteins: the linchpins of Ewing tumors. Gene 363: 1-14, 2005.
25. Toomey EC, Schiffman JD and Lessnick SL: Recent advances in the molecular pathogenesis of Ewing's sarcoma. Oncogene 29: 4504-4516, 2010.
26. Rossow KL and Janknecht R: The Ewing's sarcoma gene product functions as a transcriptional activator. Cancer Res 61: 2690-2695, 2001.
27. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, et al: Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310: 644-648, 2005.
28. Tomlins SA, Laxman B, Dhanasekaran SM, Helgeson BE, Cao X, Morris DS, Menon A, Jing X, Cao Q, Han B, et al: Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 448: 595-599, 2007.
29. Attard G, Clark J, Ambroisine L, Mills IG, Fisher G, Flohr P, Reid A, Edwards S, Kovacs G, Berney D, et al: Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer. Br J Cancer 99: 314-320, 2008.
30. Hermans KG, van der Korput HA, van Marion R, van de Wijngaart DJ, Ziel-van der Made A, Dits NF, Boormans JL, van der Kwast TH, van Dekken H, Bangma CH, et al: Truncated ETV1, fused to novel tissue-specific genes, and full-length ETV1 in prostate cancer. Cancer Res 68: 7541-7549, 2008.
31. Clark JP and Cooper CS: ETS gene fusions in prostate cancer. Nat Rev Urol 6: 429-439, 2009.
32. Shin S, Kim TD, Jin F, van Deursen JM, Dehm SM, Tindall DJ, Grande JP, Munz JM, Vasmatzis G and Janknecht R: Induction of prostatic intraepithelial neoplasia and modulation of androgen receptor by ETS variant 1/ETS-related protein 81. Cancer Res 69: 8102-8110, 2009.
33. Jane-Valbuena J, Widlund HR, Perner S, Johnson LA, Dibner AC, Lin WM, Baker AC, Nazarian RM, Vijayendran KG, Sellers WR, et al: An oncogenic role for ETV1 in melanoma. Cancer Res 70: 2075-2084, 2010.
34. Goueli BS and Janknecht R: Upregulation of the catalytic telomerase subunit by the transcription factor ER81 and oncogenic HER2/Neu, Ras, or Raf. Mol Cell Biol 24: 25-35, 2004.
35. Hiyama E and Hiyama K: Telomerase as tumor marker. Cancer Lett 194: 221-233, 2003.
36. Janknecht R: On the road to immortality: hTERT upregulation in cancer cells. FEBS Lett 564: 9-13, 2004.
37. Bosc DG and Janknecht R: Regulation of HER2/Neu promoter activity by the ETS transcription factor, ER81. J Cell Biochem 86: 174-183, 2002.
38. Signoretti S, Montironi R, Manola J, Altimari A, Tam C, Bubley G, Balk S, Thomas G, Kaplan I, Hlatky L, et al: Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst 92: 1918-1925, 2000.
39. Osman I, Mikhail M, Shuch B, Clute M, Cheli CD, Ghani F, Thiel RP and Taneja SS: Serum levels of shed Her2/neu protein in men with prostate cancer correlate with disease progression. J Urol 174: 2174-2177, 2005.
40. Nishio Y, Yamada Y, Kokubo H, Nakamura K, Aoki S, Taki T, Honda N, Nakagawa A, Saga S and Hara K: Prognostic significance of immunohistochemical expression of the HER-2/neu oncoprotein in bone metastatic prostate cancer. Urology 68: 110-115, 2006.
41. Dowdy SC, Mariani A and Janknecht R: HER2/Neu- and TAK1-mediated up-regulation of the transforming growth factor beta inhibitor Smad7 via the ETS protein ER81. J Biol Chem 278: 44377-44384, 2003.
42. Massague J: TGFbeta in cancer. Cell 134: 215-230, 2008.
43. Yan X and Chen YG: Smad7: not only a regulator, but also a cross-talk mediator of TGF-beta signalling. Biochem J 434: 1-10, 2011.
44. De Haro L and Janknecht R: Functional analysis of the transcription factor ER71 and its activation of the matrix metalloproteinase-1 promoter. Nucleic Acids Res 30: 2972-2979, 2002.
45. De Haro L and Janknecht R: Cloning of the murine ER71 gene (Etsrp71) and initial characterization of its promoter. Genomics 85: 493-502, 2005.
46. Goueli BS and Janknecht R: Regulation of telomerase reverse transcriptase gene activity by upstream stimulatory factor. Oncogene 22: 8042-8047, 2003.
47. Shin S and Janknecht R: Concerted activation of the Mdm2 promoter by p72 RNA helicase and the coactivators p300 and P/CAF. J Cell Biochem 101: 1252-1265, 2007.
48. Kim TD, Oh S, Shin S and Janknecht R: Regulation of tumor suppressor p53 and HCT116 cell physiology by histone demethylase JMJD2D/KDM4D. PLoS One 7: e34618, 2012.
49. Kim TD, Shin S and Janknecht R: Repression of Smad3 activity by histone demethylase SMCX/JARID1C. Biochem Biophys Res Commun 366: 563-567, 2008.
50. Rossow KL and Janknecht R: Synergism between p68 RNA helicase and the transcriptional coactivators CBP and p300. Oncogene 22: 151-156, 2003.
51. Ben-Levy R, Paterson HF, Marshall CJ and Yarden Y: A single autophosphorylation site confers oncogenicity to the Neu/ErbB-2 receptor and enables coupling to the MAP kinase pathway. EMBO J 13: 3302-3311, 1994.
52. Knebel J, De Haro L and Janknecht R: Repression of transcription by TSGA/Jmjd1a, a novel interaction partner of the ETS protein ER71. J Cell Biochem 99: 319-329, 2006.
53. Mooney SM, Goel A, D'Assoro AB, Salisbury JL and Janknecht R: Pleiotropic effects of p300-mediated acetylation on p68 and p72 RNA helicase. J Biol Chem 285: 30443-30452, 2010.
54. Kim J, Shin S, Subramaniam M, Bruinsma E, Kim TD, Hawse JR, Spelsberg TC and Janknecht R: Histone demethylase JARID1B/KDM5B is a corepressor of TIEG1/KLF10. Biochem Biophys Res Commun 401: 412-416, 2010.
55. Shin S and Janknecht R: Activation of androgen receptor by histone demethylases JMJD2A and JMJD2D. Biochem Biophys Res Commun 359: 742-746, 2007.
56. Mooney SM, Grande JP, Salisbury JL and Janknecht R: Sumoylation of p68 and p72 RNA helicases affects protein stability and transactivation potential. Biochemistry 49: 1-10, 2010.
57. Shin S and Janknecht R: Diversity within the JMJD2 histone demethylase family. Biochem Biophys Res Commun 353: 973-977, 2007.
58. Shin S, Bosc DG, Ingle JN, Spelsberg TC and Janknecht R: Rcl is a novel ETV1/ER81 target gene upregulated in breast tumors. J Cell Biochem 105: 866-874, 2008.
59. Shin S, Rossow KL, Grande JP and Janknecht R: Involvement of RNA helicases p68 and p72 in colon cancer. Cancer Res 67: 7572-7578, 2007.
60. Oh S and Janknecht R: Histone demethylase JMJD5 is essential for embryonic development. Biochem Biophys Res Commun 420: 61-65, 2012.
61. Kim TD, Shin S, Berry WL, Oh S and Janknecht R: The JMJD2A demethylase regulates apoptosis and proliferation in colon cancer cells. J Cell Biochem 113: 1368-1376, 2012.
62. Ozaki I, Mizuta T, Zhao G, Yotsumoto H, Hara T, Kajihara S, Hisatomi A, Sakai T and Yamamoto K: Involvement of the Ets-1 gene in overexpression of matrilysin in human hepatocellular carcinoma. Cancer Res 60: 6519-6525, 2000.
63. Crawford HC, Fingleton B, Gustavson MD, Kurpios N, Wagenaar RA, Hassell JA and Matrisian LM: The PEA3 subfamily of Ets transcription factors synergizes with beta-catenin-LEF-1 to activate matrilysin transcription in intestinal tumors. Mol Cell Biol 21: 1370-1383, 2001.
64. Wei GH, Badis G, Berger MF, Kivioja T, Palin K, Enge M, Bonke M, Jolma A, Varjosalo M, Gehrke AR, et al: Genome-wide analysis of ETS-family DNA-binding in vitro and in vivo. EMBO J 29: 2147-2160, 2010.
65. Janknecht R, Monte D, Baert JL and de Launoit Y: The ETS-related transcription factor ERM is a nuclear target of signaling cascades involving MAPK and PKA. Oncogene 13: 1745-1754, 1996.
66. Holbro T, Civenni G and Hynes NE: The ErbB receptors and their role in cancer progression. Exp Cell Res 284: 99-110, 2003.
67. Cai C, Hsieh CL, Omwancha J, Zheng Z, Chen SY, Baert JL and Shemshedini L: ETV1 is a novel androgen receptor-regulated gene that mediates prostate cancer cell invasion. Mol Endocrinol 21: 1835-1846, 2007.
68. Kumar-Sinha C, Tomlins SA and Chinnaiyan AM: Recurrent gene fusions in prostate cancer. Nat Rev Cancer 8: 497-511, 2008.
69. Yu YP, Landsittel D, Jing L, Nelson J, Ren B, Liu L, McDonald C, Thomas R, Dhir R, Finkelstein S, et al: Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol 22: 2790-2799, 2004.
70. Pajouh MS, Nagle RB, Breathnach R, Finch JS, Brawer MK and Bowden GT: Expression of metalloproteinase genes in human prostate cancer. J Cancer Res Clin Oncol 117: 144-150, 1991.
71. Hashimoto K, Kihira Y, Matuo Y and Usui T: Expression of matrix metalloproteinase-7 and tissue inhibitor of metalloproteinase-1 in human prostate. J Urol 160: 1872-1876, 1998.
72. Ouyang XS, Wang X, Lee DT, Tsao SW and Wong YC: Up-regulation of TRPM-2, MMP-7 and ID-1 during sex hormone-induced prostate carcinogenesis in the Noble rat. Carcinogenesis 22: 965-973, 2001.
73. Asamoto M, Hokaiwado N, Cho YM, Takahashi S, Ikeda Y, Imaida K and Shirai T: Prostate carcinomas developing in transgenic rats with SV40 T antigen expression under probasin promoter control are strictly androgen dependent. Cancer Res 61: 4693-4700, 2001.
74. Szarvas T, Becker M, Vom Dorp F, Meschede J, Scherag A, Bankfalvi A, Reis H, Schmid KW, Romics I, Rubben H and Ergun S: Elevated serum matrix metalloproteinase 7 levels predict poor prognosis after radical prostatectomy. Int J Cancer 128: 1486-1492, 2011.
75. Wilson CL, Heppner KJ, Labosky PA, Hogan BL and Matrisian LM: Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc Natl Acad Sci USA 94: 1402-1407, 1997.
76. Rudolph-Owen LA, Chan R, Muller WJ and Matrisian LM: The matrix metalloproteinase matrilysin influences early-stage mammary tumorigenesis. Cancer Res 58: 5500-5506, 1998.
77. Crawford HC, Scoggins CR, Washington MK, Matrisian LM and Leach SD: Matrix metalloproteinase-7 is expressed by pancreatic cancer precursors and regulates acinar-to-ductal metaplasia in exocrine pancreas. J Clin Invest 109: 1437-1444, 2002.
78. Hollenhorst PC, Ferris MW, Hull MA, Chae H, Kim S and Graves BJ: Oncogenic ETS proteins mimic activated RAS/MAPK signaling in prostate cells. Genes Dev 25: 2147-2157, 2011.
79. Powell WC, Knox JD, Navre M, Grogan TM, Kittelson J, Nagle RB and Bowden GT: Expression of the metalloproteinase matrilysin in DU-145 cells increases their invasive potential in severe combined immunodeficient mice. Cancer Res 53: 417-422, 1993.
80. Wroblewski LE, Noble PJ, Pagliocca A, Pritchard DM, Hart CA, Campbell F, Dodson AR, Dockray GJ and Varro A: Stimulation of MMP-7 (matrilysin) by Helicobacter pylori in human gastric epithelial cells: role in epithelial cell migration. J Cell Sci 116: 3017-3026, 2003.
81. Remy L, Trespeuch C, Bachy S, Scoazec JY and Rousselle P: Matrilysin 1 influences colon carcinoma cell migration by cleavage of the laminin-5 beta3 chain. Cancer Res 66: 11228-11237, 2006.
82. Lee SK, Han YM, Yun J, Lee CW, Shin DS, Ha YR, Kim J, Koh JS, Hong SH, Han DC and Kwon BM: Phosphatase of regenerating liver-3 promotes migration and invasion by upregulating matrix metalloproteinases-7 in human colorectal cancer cells. Int J Cancer 131: E190-E203, 2012.
83. Ii M, Yamamoto H, Adachi Y, Maruyama Y and Shinomura Y: Role of matrix metalloproteinase-7 (matrilysin) in human cancer invasion, apoptosis, growth, and angiogenesis. Exp Biol Med (Maywood) 231: 20-27, 2006.
84. Egeblad M and Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161-174, 2002.
85. Deryugina EI and Quigley JP: Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 25: 9-34, 2006.
86. Wang Y, Wang L, Chen Y, Li L, Yang X, Li B, Song S, Yang L, Hao Y and Yang J: ER81 expression in breast cancers and hyperplasia. Pathology Res Int 2011: 980513, 2011.
87. Chi P, Chen Y, Zhang L, Guo X, Wongvipat J, Shamu T, Fletcher JA, Dewell S, Maki RG, Zheng D, et al: ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. Nature 467: 849-853, 2010.